Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a ...

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

The logic suggested by the Lilly trial is the opposite, however. It proposes that being overweight is a primary cause of unemployment, and that if you can cure people of being fat, you can cure them ...

Those include GLP-1s for obesity such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which both carry hefty price tags of roughly $1,000 per month before insurance and other rebates.

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Goldman Sachs analyst Salveen Richter has reiterated their bullish stance on AMGN stock, giving a Buy rating yesterday. Salveen Richter has ...